ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes

<p><strong>Objectives</strong></p> <p>The use of aspirin for the secondary prevention of cardiovascular disease (CVD) is firmly established, and the proportional reductions in heart attacks and strokes appear to be similar in people with and without diabetes. Uncertaint...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Bowman, L, Mafham, M, Stevens, W, Haynes, R, Buck, G, Collins, R, Armitage, J, ASCEND Study Collaborative Group
Natura:	Journal article
Pubblicazione:	Elsevier 2017

Documenti analoghi

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
di: Parish, S, et al.
Pubblicazione: (2022)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
di: Emily L. Sammons, et al.
Pubblicazione: (2024-11-01)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
di: Sarah Parish, et al.
Pubblicazione: (2023-03-01)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
di: Sammons, E, et al.
Pubblicazione: (2024)

ASCEND-Eye: effects of omega-3 fatty acids on diabetic retinopathy
di: Sammons, E, et al.
Pubblicazione: (2023)

ASCEND-eye: rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
di: Sammons, E, et al.
Pubblicazione: (2023)

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
di: Emily Sammons, et al.
Pubblicazione: (2023-10-01)

Effects of aspirin for primary prevention in persons with diabetes mellitus
di: Bowman, L, et al.
Pubblicazione: (2018)

Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
di: Aung, T, et al.
Pubblicazione: (2016)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
di: Parish, S, et al.
Pubblicazione: (2023)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
di: Sammons, EL, et al.
Pubblicazione: (2024)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
di: Sammons, EL, et al.
Pubblicazione: (2024)

Effects of omega−3 fatty acid supplements on arrhythmias
di: Parish, S, et al.
Pubblicazione: (2020)

Aspirin for primary prevention of vascular disease in people with diabetes.
di: Haynes, R, et al.
Pubblicazione: (2009)

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
di: Petrucci, G, et al.
Pubblicazione: (2024)

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes
di: Praveen Patel, et al.
Pubblicazione: (2025-02-01)

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
di: Mafham, MM, et al.
Pubblicazione: (2019)

The ASCEND-Eye study: effect(s) of aspirin and omega-3 fatty acids on eye disease
di: Sammons, E
Pubblicazione: (2023)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
di: Aung, T, et al.
Pubblicazione: (2017)

Effects of n-3 fatty acid supplements in diabetes mellitus
di: Ascend Study Collaborative Group, et al.
Pubblicazione: (2018)

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
di: Rocca, B, et al.
Pubblicazione: (2020)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
di: Harper, C, et al.
Pubblicazione: (2021)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
di: Harper, C, et al.
Pubblicazione: (2021)

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.
di: Andrea K Viecelli, et al.
Pubblicazione: (2019-01-01)

Performance of the UKPDS Outcomes Model 2 in a contemporary UK type 2 diabetes trial cohort
di: Keng, MJ, et al.
Pubblicazione: (2021)

Comparison of effectiveness of low-dose aspirin versus omega-3 fatty acids as adjuvants to nonsurgical periodontal therapy in Type II diabetic patients with chronic periodontitis
di: Prathyusha Rampally, et al.
Pubblicazione: (2019-01-01)

Granulation tissue enriched by aspirin and omega-3 fatty acids in healing experimental periodontal lesion
di: Filip Hromcik, et al.
Pubblicazione: (2021-06-01)

Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
di: Hartweg, J, et al.
Pubblicazione: (2008)

Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
di: Hartweg, J, et al.
Pubblicazione: (2008)

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia.
di: Eugene Han, et al.
Pubblicazione: (2016-01-01)

Synergistic effects of omega-3 polyunsaturated fatty acids and aspirin in the clinical practice – a narrative review
di: Zajac-Grabiec Anna, et al.
Pubblicazione: (2024-03-01)

Omega-3 fatty acids, insulin resistance and type 2 diabetes
di: Leila Azadbakht, et al.
Pubblicazione: (2011-01-01)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
di: Price, H, et al.
Pubblicazione: (2009)

Aspirin for primary prevention of cardiovascular disease in diabetes
di: Ying Xing, et al.
Pubblicazione: (2019-07-01)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
di: Emberson, JR, et al.
Pubblicazione: (2007)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
di: Cull, C, et al.
Pubblicazione: (2004)

Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
di: Tajuddin N, et al.
Pubblicazione: (2016-04-01)

Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients
di: Pasquale Mone, et al.
Pubblicazione: (2022-03-01)

The relationship of dietary omega-3 fatty acid and omega-6 to omega-3 ratio intake and likelihood of type 2 diabetes in a cross-sectional study
di: Ebrahim Shakiba, et al.
Pubblicazione: (2024-11-01)

Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
di: Collins, R, et al.
Pubblicazione: (1996)